The use of the monoclonal antibody tocilizumab revolutionized CRS management by interrupting the proinflammatory signaling cascade via IL-6 blockade without impacting CAR T cell efficacy (95, 103). This evidence concerns the gene IL6 and congenital rubella syndrome.